TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced the company and the University of Tokyo have entered the second phase of collaboration for co-creating new medicines and medical solutions, called the Astellas Alliance Acceleration Program. The University of Tokyo will expand its partnership involvement to include all of its institutions. A newly appointed AAAP-dedicated project manager will be stationed at the university to facilitate the collaboration.
Yoshitsugu Shitaka, Chief Scientific Officer at Astellas, said: 'By leveraging the power of the more extensive and closer collaboration, we expect to accelerate the co-creation of innovations that contribute to our activities from early drug discovery research to clinical development.'
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX